Event Registration

Summary

In this webinar, we will explore how mouse models, using different formats of human natural killer (NK) cells and human cancer cells, can be leveraged to evaluate the efficacy of biologics to amplify tumor control. Our group’s expertise is in design and translation of cytokine-bearing (IL-15) biologics within the context of cancer.

We have tested and developed a variety of these biologics, with particular focus on Tri-specific Killer Engagers (TriKE), which contain an NK cell binding arm (anti-CD16), a tumor-associated binding arm (TAA) that can be swapped out to target a variety of tumors, and an IL-15 moiety in the middle. Using NSG mice as a backbone to our in vivo research, we have developed acute myeloid leukemia (AML), prostate cancer, head and neck cancer, lung cancer, and ovarian cancer models to explore how TriKE molecules, and other biologics, impact tumor growth through NK cells. Within these models we have explored how enriched (CD3/CD19 depleted) NK cells, expanded NK cells, and engineered NK cells elicit control.

Recent work has focused on state-of-the-art humanized mouse models (NSG-F15 platform) to explore therapeutic efficacy in more complex immune systems and evaluate how NK cell activation by biologics results in cross-talk within the tumor microenvironment. As we move into the clinic with several of these biologics, the goal is to develop a platform where we can better explore therapeutic success and failure with these molecules in order to influence molecule and clinical trial design to improve outcomes.

In this webinar, we will explore:

NK cell immunotherapy and how we are using in vitro and in vivo models to test them
Different biologics (primarily TriKEs) and xenogeneic mouse models of human cancer employed to test them (AML, prostate cancer, head and neck cancer, lung cancer, and ovarian cancer)
Humanized mouse models that can be leveraged to better explore NK cell therapeutics and immune interactions

*NSG is a registered trademark in the USA and other countries

JAX^® Webinars are complimentary.
No fees will be charged for registering.

Webinars are 45-50 minutes long, followed by a Q&A session.

When registering, please use an institutional (e.g. work, university, etc.) email address or contact our event staff to request an exception. Thank you.

Exploring Biologics to Drive NK Cell Immunotherapy in Mouse Models of Human Cancer

When registering, please use an institutional (e.g. work, university, etc.) email address or contact our event staff to request an exception. Thank you.